top of page


Mar 13, 2024

Governor Lujan Grisham, State Legislature “Draw a Line in the Sand to the Benefit of All New Mexicans” by Requiring Transparency and Fair Community Pharmacy Reimbursements

SANTA FE, NM (March 12, 2024) – Pharmacists United for Truth and Transparency (PUTT) applauds New Mexico Governor Michelle Lujan Grisham and the State Legislature for enacting HB 33, the “Prescription Drug Price Transparency Act”, which requires organizations that set or influence the price consumers pay for prescription medication at the pharmacy counter to begin regularly reporting drug price increases and other data to the state’s Department of Insurance.

Governor Lujan Grisham also signed HB 165, a law requiring pharmacy benefit managers (PBMs) to reimburse the state’s community pharmacies at the National Drug Acquisition Cost (NADAC) plus a dispensing fee to help offset the costs associated with prescription bottles, labels, staff and overhead. NADAC is maintained by the Centers for Medicare and Medicaid Services and is the only publicly-available drug pricing index. Both HB 33 and HB 165 take effect on March 1, 2025.

“We appreciate Governor Lujan Grisham’s tenacity and commitment to New Mexicans, and the Legislature’s willingness to stand up for their state’s patients and community pharmacies,” said PUTT Executive Director Monique Whitney. “At a time when as many as 30 percent of our country’s independent pharmacies are facing the possibility of having to close because of below-cost reimbursements and PBM network contracts with nearly impossible terms, we’re proud of the Governor and the Roundhouse for drawing a line in the sand to the benefit of all New Mexicans.”

PBMs manage patients’ prescription drug benefit, acting as the liaison between the patient, the pharmacy, and the patient’s employer or health plan sponsor. Since 2019, numerous studies have uncovered evidence suggesting certain PBM practices - including exorbitant spread pricing, in which PBMs bill the end payer more than the pharmacy was reimbursed; and “steering” patients from their pharmacy of choice to PBM-owned/affiliated pharmacies – increase patients’ and end payers’ costs. Additional studies have shown the drug manufacturer rebates PBMs negotiate contribute to a drug’s list price year over year, causing patients to pay more out of pocket because of rebate-inflated costs. To understand how PBM practices affect patient care and affordability of medication for consumers and end payers, visit PUTT’s website at

# # #

bottom of page